Monitoring for initial LMWH therapy, including bridging

  • Baseline PT/aPTT
  • Baseline hematocrit and q2-5 days during first 2 weeks of LMWH therapy, and prn if bleeding is suspected or confirmed
  • Baseline platelet count, and q2-5 days during first 2 weeks of LMWH therapy
  • Baseline serum creatinine, and q2-5days during first 2 weeks of LMWH therapy, and prn if change in renal function is suspected, or if bleeding is suspected or confirmed